Cyclosporine (Atopica)

Cyclosporine is a powerful immunosuppressant medication that has revolutionized the treatment of canine atopic dermatitis and other immune-mediated skin conditions in dogs. Marketed under the brand name Atopica for veterinary use, this medication belongs to the calcineurin inhibitor class of immunomodulatory drugs. Originally developed for preventing organ transplant rejection in humans, cyclosporine has proven remarkably effective at controlling the overactive immune responses that drive allergic skin disease in dogs. The veterinary formulation of cyclosporine has become a cornerstone of dermatological therapy, offering long-term management options for dogs suffering from chronic allergic conditions that significantly impact their quality of life.

Cyclosporine works by selectively suppressing T-lymphocyte activation and the production of inflammatory cytokines that trigger allergic responses in the skin. When a dog with atopic dermatitis encounters environmental allergens such as pollen, dust mites, or mold spores, their immune system overreacts and produces an inflammatory cascade that results in intense itching, redness, and skin damage. Cyclosporine interrupts this cascade by inhibiting calcineurin, an enzyme essential for T-cell activation and cytokine production. This targeted immunomodulation reduces inflammation without completely suppressing the entire immune system, allowing dogs to maintain reasonable immune function while experiencing significant relief from allergic symptoms.

The veterinary formulation of cyclosporine is available as oral capsules in multiple sizes to accommodate the wide range of dog sizes, from small breeds to giant breeds. Atopica capsules contain a modified form of cyclosporine that provides improved and more consistent absorption compared to earlier formulations. The medication is typically administered once daily, though some dogs may eventually be transitioned to every-other-day dosing once their condition is well controlled. The capsules should be given consistently either with or without food, as food can affect absorption rates. Many veterinarians recommend giving cyclosporine on an empty stomach for optimal absorption, though this may be adjusted based on individual tolerance.

While cyclosporine is generally well-tolerated in dogs when prescribed and monitored appropriately, it requires careful veterinary supervision throughout treatment. Because it modifies immune function, dogs taking cyclosporine need regular monitoring to ensure they remain healthy and that the medication continues to work effectively. Veterinarians typically recommend baseline blood work before starting treatment and periodic monitoring thereafter. The importance of following prescribed dosing protocols cannot be overstated, as both under-dosing and over-dosing can lead to suboptimal outcomes. Pet owners should work closely with their veterinarian to establish an effective treatment plan and maintain regular follow-up appointments to assess their dog's response to therapy.

The primary indication for cyclosporine in dogs is the control of clinical manifestations of canine atopic dermatitis, a chronic allergic skin condition that affects a significant percentage of the dog population. Atopic dermatitis is one of the most common dermatological conditions seen in veterinary practice, characterized by intense pruritus, recurrent skin infections, and progressive skin changes that severely impact affected dogs' comfort and quality of life. Cyclosporine addresses the underlying immune dysfunction that drives atopic dermatitis, providing sustained relief from itching and allowing damaged skin to heal. For dogs with moderate to severe atopic dermatitis that requires long-term management, cyclosporine has become a first-line treatment option recommended by veterinary dermatologists worldwide.

Canine atopic dermatitis typically develops in dogs between one and three years of age and tends to worsen over time without appropriate treatment. Affected dogs experience intense itching that leads to constant scratching, licking, chewing, and rubbing of affected areas. Common sites of involvement include the face, ears, paws, armpits, groin, and abdomen. The chronic inflammation and self-trauma from scratching predispose affected dogs to secondary bacterial and yeast infections, which further compound the discomfort and skin damage. Cyclosporine helps break this cycle by reducing the inflammatory response that initiates the itch-scratch cycle, allowing the skin barrier to recover and reducing susceptibility to secondary infections.

Beyond atopic dermatitis, cyclosporine has demonstrated efficacy in treating several other immune-mediated and inflammatory conditions in dogs. Perianal fistulas, also known as anal furunculosis, represent a particularly challenging condition that responds well to cyclosporine therapy. This painful condition primarily affects German Shepherd Dogs and involves deep, draining tracts around the anus that cause significant discomfort and are notoriously difficult to treat with other medications. Cyclosporine has transformed the management of perianal fistulas, often achieving remission in cases that previously required surgical intervention. Many dogs with perianal fistulas require long-term cyclosporine maintenance to prevent recurrence.

Veterinarians also prescribe cyclosporine for various other immune-mediated conditions, though some of these uses are considered off-label. These include certain forms of immune-mediated hemolytic anemia, inflammatory bowel disease, keratoconjunctivitis sicca (dry eye), sebaceous adenitis, and other autoimmune skin disorders. In these conditions, cyclosporine's ability to modulate excessive immune responses provides therapeutic benefit where other treatments may have failed or produced unacceptable side effects. The medication may be used alone or in combination with other immunomodulatory drugs depending on the specific condition and its severity.

When selecting cyclosporine for treatment, veterinarians consider numerous factors including the severity of the condition, previous treatment responses, concurrent health issues, and long-term management goals. Cyclosporine is often chosen when dogs require sustained immunomodulation but cannot tolerate long-term corticosteroid therapy due to side effects. Unlike corticosteroids, cyclosporine does not cause the polydipsia, polyuria, polyphagia, muscle wasting, and other systemic effects associated with chronic steroid use. This makes cyclosporine an attractive option for long-term management of chronic conditions, particularly in dogs that will require ongoing therapy for months or years. The cost of cyclosporine therapy is higher than some alternatives, but many pet owners find the improved quality of life and reduced side effect profile justify the investment.

Cyclosporine dosing in dogs follows a weight-based protocol that requires precise determination of the patient's body weight and careful selection of appropriate capsule sizes. The prescribing veterinarian determines the exact dose based on the individual dog's weight, the condition being treated, and various patient-specific factors that may influence drug metabolism and response. Because cyclosporine has a relatively narrow therapeutic window and responses can vary between individuals, dosing must be carefully tailored to each patient. Pet owners should never adjust dosing without veterinary guidance, as both under-dosing and over-dosing can lead to treatment failure or adverse effects. Accurate and regular weighing of the dog helps ensure appropriate dosing, particularly for growing dogs or those experiencing weight changes.

The typical starting dose for canine atopic dermatitis is administered once daily, with the specific milligram amount calculated based on the dog's body weight in kilograms. Atopica capsules are available in multiple sizes to facilitate accurate dosing across the wide range of dog sizes. For small dogs, precise dosing may require using specific capsule size combinations to achieve the target dose. Giant breed dogs may require multiple capsules per dose. The veterinarian will select the most practical capsule combination that achieves appropriate dosing while considering the owner's ability to administer the medication consistently. Some dogs may require dose adjustments during the initial treatment period based on their clinical response.

Treatment duration with cyclosporine varies considerably depending on the condition being treated and individual patient response. For atopic dermatitis, cyclosporine is typically considered a long-term or lifelong therapy since the underlying allergic condition cannot be cured. However, many dogs achieve sufficient disease control that allows reduction in dosing frequency after the initial treatment period. After four to eight weeks of daily dosing, veterinarians often attempt to taper the frequency to every other day while maintaining clinical control. Some dogs can eventually be maintained on twice-weekly dosing, while others require continued daily or every-other-day administration. The goal is to find the minimum effective dose that maintains adequate symptom control.

Cyclosporine capsules should be administered consistently with regard to meals, as food significantly affects absorption. For optimal and consistent absorption, administration on an empty stomach at least one hour before or two hours after feeding is often recommended. However, some dogs experience gastrointestinal upset when taking cyclosporine on an empty stomach, and these patients may tolerate the medication better when given with a small amount of food. If food is given with cyclosporine, the same feeding protocol should be followed consistently to maintain predictable drug absorption. The capsules should be given whole and not opened, crushed, or mixed with food, as this can affect drug stability and absorption.

If a dose of cyclosporine is missed, pet owners should give the missed dose as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Owners should never give two doses at once to make up for a missed dose, as this could result in overdosing and increased risk of side effects. For dogs on every-other-day maintenance dosing, a single missed dose is unlikely to cause immediate disease flare, but consistent adherence to the dosing schedule is important for maintaining disease control. Setting reminders or incorporating medication administration into daily routines can help ensure doses are not forgotten.

Completing the prescribed treatment course and maintaining regular follow-up appointments is essential for successful cyclosporine therapy. Unlike antibiotics where a defined treatment course cures the infection, cyclosporine therapy for allergic conditions typically requires ongoing treatment. Stopping cyclosporine abruptly once symptoms improve often leads to disease relapse, sometimes within weeks of discontinuation. Veterinarians work with pet owners to establish the most effective long-term management strategy, which may involve seasonal adjustments in dosing for dogs with seasonal allergies or consistent year-round therapy for those with perennial symptoms. Regular recheck examinations allow the veterinarian to assess treatment efficacy, monitor for side effects, and adjust the treatment plan as needed.

Cyclosporine is generally well-tolerated by most dogs when prescribed at appropriate doses and administered correctly, though side effects can occur and owners should be aware of what to monitor during treatment. The majority of dogs receiving cyclosporine for atopic dermatitis experience significant improvement in their skin condition and quality of life with manageable or no adverse effects. However, as with any medication that modifies immune function, careful monitoring is important to detect any problems early. Pet owners play a crucial role in observing their dogs for changes that might indicate adverse reactions and reporting these observations to their veterinarian promptly.

The most commonly observed side effects of cyclosporine in dogs involve the gastrointestinal system, particularly during the initial weeks of treatment. Vomiting, diarrhea, decreased appetite, and soft stools occur in a notable percentage of dogs starting cyclosporine therapy. These gastrointestinal effects are usually mild to moderate and often improve or resolve as the dog's system adjusts to the medication, typically within the first few weeks of treatment. Administering cyclosporine with food may help reduce gastrointestinal upset in some dogs, though this should be done consistently if implemented. Temporarily freezing the capsules before administration has also been reported to help reduce nausea in some patients. If gastrointestinal effects persist or are severe, veterinarians may recommend temporary dose reduction or other management strategies.

Moderate side effects that may warrant veterinary attention include persistent gastrointestinal symptoms, gingival hyperplasia (overgrowth of gum tissue), excessive hair growth or coat texture changes, and papillomatosis (development of wart-like growths). Gingival hyperplasia occurs in some dogs on long-term cyclosporine therapy and appears as thickened, sometimes inflamed gum tissue. While often not clinically significant, severe cases may require dose reduction or discontinuation. Papillomatosis, the development of benign viral warts, can occur because cyclosporine's immunosuppressive effects may allow latent papillomavirus infections to become active. These growths are usually benign and may resolve with dose reduction, but should be evaluated by a veterinarian to rule out other causes.

Serious side effects requiring immediate veterinary attention are uncommon but can occur. Because cyclosporine suppresses certain aspects of immune function, dogs receiving this medication may be more susceptible to infections or may have difficulty fighting off infections they acquire. Signs of infection such as fever, lethargy, loss of appetite, or localized signs like wound drainage should prompt immediate veterinary evaluation. Severe allergic reactions to cyclosporine are rare but possible, and signs such as facial swelling, difficulty breathing, hives, or collapse require emergency veterinary care. Additionally, long-term immunosuppression has theoretical concerns regarding increased cancer risk, though this has not been definitively established in dogs at typical therapeutic doses.

Rare side effects and long-term considerations with cyclosporine therapy include potential effects on organ function and the possibility of opportunistic infections. Periodic blood work monitoring helps detect any early signs of liver or kidney effects, though clinically significant organ toxicity is uncommon at standard doses. Dogs on cyclosporine should avoid vaccination with modified-live vaccines due to their immunosuppressed state, as these vaccines could potentially cause disease rather than protection. Killed vaccines are generally considered safe but may produce reduced immune responses. Pet owners should inform any veterinarian treating their dog that the pet is receiving cyclosporine, as this information is important for treatment decisions. Any unusual symptoms, behavioral changes, or new health concerns in a dog receiving cyclosporine should be reported to the prescribing veterinarian.

Cyclosporine should not be administered to dogs with known hypersensitivity or allergy to cyclosporine or any components of the formulation. While true allergic reactions to cyclosporine are uncommon, dogs that have experienced hypersensitivity reactions to this medication in the past should not receive it again. Cross-reactivity with other calcineurin inhibitors such as tacrolimus is theoretically possible, so dogs with known reactions to related compounds should be treated with caution. Pet owners should inform their veterinarian of any previous adverse reactions to medications their dog has experienced, as this history helps guide safe prescribing decisions.

Dogs with pre-existing liver or kidney disease require careful evaluation before starting cyclosporine therapy, and the medication may be contraindicated in cases of significant organ dysfunction. Cyclosporine is metabolized primarily by the liver, and impaired hepatic function can lead to drug accumulation and increased risk of toxicity. Dogs with elevated liver enzymes or clinical signs of liver disease should undergo thorough evaluation before cyclosporine is prescribed. Similarly, while cyclosporine is not primarily eliminated through the kidneys, renal impairment may affect overall drug handling and increase susceptibility to adverse effects. Baseline blood work including liver and kidney function tests is essential before initiating therapy.

The use of cyclosporine in pregnant or nursing dogs has not been adequately studied, and the medication should be avoided in these patients unless the potential benefits clearly outweigh the risks. Studies in other species have shown that cyclosporine can cross the placenta and may affect fetal development. The drug is also excreted in milk, potentially exposing nursing puppies to immunosuppressive effects. Intact female dogs receiving cyclosporine should be prevented from breeding during treatment. Male dogs on cyclosporine therapy may have temporarily reduced fertility, though this typically reverses after discontinuation. Dogs intended for breeding should complete any necessary cyclosporine treatment and allow adequate washout time before breeding attempts.

Cyclosporine is contraindicated in dogs with active systemic infections, including bacterial, viral, fungal, or parasitic infections that have not been adequately controlled. Because cyclosporine suppresses certain immune functions, it can impair the body's ability to fight infections and may allow existing infections to worsen or spread. Dogs should be free of significant infections before starting cyclosporine therapy. Those with chronic conditions that predispose to infection require careful consideration of risks and benefits. Additionally, dogs with malignant neoplasia (cancer) should generally not receive cyclosporine due to theoretical concerns about immunosuppression potentially affecting tumor surveillance and growth. A complete medical history and thorough physical examination help identify any conditions that might contraindicate cyclosporine use.

Informing your veterinarian about all medications, supplements, and treatments your dog is currently receiving is essential before starting cyclosporine therapy. Drug interactions can significantly affect cyclosporine levels in the body, potentially leading to either toxicity from elevated levels or treatment failure from reduced levels. Cyclosporine is metabolized by the cytochrome P450 enzyme system in the liver, and many other drugs can inhibit or induce these enzymes, altering cyclosporine metabolism. Additionally, cyclosporine itself can affect the metabolism and action of other medications. A complete medication history allows your veterinarian to identify potential interactions and make appropriate dosing adjustments or alternative treatment selections.

Several important drug interactions have been documented with cyclosporine in veterinary medicine. Ketoconazole and other azole antifungal medications significantly inhibit cyclosporine metabolism, leading to increased cyclosporine blood levels. While this interaction is sometimes intentionally utilized to reduce cyclosporine dosing requirements and cost, it must be carefully managed by a veterinarian. Other drugs that may increase cyclosporine levels include certain antibiotics such as erythromycin and metronidazole, calcium channel blockers, and various other medications. Conversely, drugs that may decrease cyclosporine levels include certain anticonvulsants, rifampin, and other enzyme-inducing medications. Changes in concurrent medications during cyclosporine therapy may necessitate dose adjustments.

Cyclosporine can interact with various supplements and dietary components that dog owners commonly use. Grapefruit and grapefruit juice are known to inhibit cyclosporine metabolism and should be avoided. Certain herbal supplements, particularly St. John's Wort, can significantly reduce cyclosporine levels and should not be given to dogs receiving this medication. Fish oil supplements, often used for skin health, do not have significant direct interactions with cyclosporine but may provide complementary benefits for dogs with allergic skin disease. Probiotics and digestive supplements are generally considered safe to use concurrently. However, owners should discuss any supplements with their veterinarian before adding them to their dog's regimen.

Monitoring for drug interactions during cyclosporine therapy involves both clinical observation and periodic blood testing. Signs of cyclosporine toxicity from elevated drug levels may include increased gastrointestinal effects, gingival overgrowth, or signs of infection from excessive immunosuppression. Signs of inadequate cyclosporine levels include return or worsening of allergic symptoms. Therapeutic drug monitoring through blood level testing may be recommended in certain situations, such as when interacting medications cannot be avoided or when clinical response is unexpectedly poor or excessive. Whenever new medications are prescribed by any veterinarian, pet owners should mention that their dog is receiving cyclosporine to ensure potential interactions are considered.

Several general precautions apply to all dogs receiving cyclosporine therapy. Because this medication modifies immune function, dogs taking cyclosporine should be monitored for any signs of infection and should receive prompt veterinary attention if illness develops. Regular wellness examinations and recommended blood work monitoring help ensure the medication continues to be safe for the individual patient. Pet owners should accurately track their dog's weight, as significant weight changes may require dosing adjustments. Following the veterinarian's instructions precisely regarding dose, timing, and administration ensures optimal therapeutic outcomes while minimizing risks.

Certain breeds may require special consideration when cyclosporine therapy is being considered. Dogs with the MDR1 (ABCB1) gene mutation, common in Collies, Australian Shepherds, Shetland Sheepdogs, and other herding breeds, may have altered drug transport and metabolism. While cyclosporine is not considered a high-risk drug for MDR1-affected dogs at standard doses, the interaction between cyclosporine and MDR1 status can affect other concurrently administered medications. German Shepherd Dogs, which are predisposed to perianal fistulas often treated with cyclosporine, may have breed-specific metabolic characteristics. Veterinarians consider breed when prescribing cyclosporine and may recommend MDR1 genetic testing for at-risk breeds receiving multiple medications.

Proper handling of cyclosporine capsules protects both the dog and household members. Cyclosporine is an immunosuppressive agent, and human exposure should be minimized, particularly for pregnant women, individuals with compromised immune systems, and children. The capsules should not be opened, and hands should be washed after administration. The medication should be stored securely away from children and pets, as accidental ingestion could be harmful. In multi-pet households, the treated dog should be monitored to ensure other pets do not consume the medication. Any spillage should be cleaned promptly.

During cyclosporine treatment, owners should monitor their dogs for signs of both therapeutic response and potential adverse effects. Improvement in skin condition, reduced scratching, and healing of lesions indicate positive response to therapy. Conversely, persistent or worsening symptoms may indicate inadequate dosing or the need for alternative or adjunctive treatments. Signs to report to the veterinarian include excessive vomiting or diarrhea, lethargy, decreased appetite, signs of infection such as fever or discharge, unusual lumps or growths, or any other concerning changes. Keeping a log of symptoms and medication administration can help track response and identify patterns.

Special populations require additional considerations when cyclosporine is prescribed. Geriatric dogs may have age-related changes in liver and kidney function that affect drug metabolism and may require dose adjustments or more frequent monitoring. Very young dogs have immature metabolic systems and generally should not receive cyclosporine unless specifically indicated and carefully monitored. Dogs with concurrent chronic diseases such as diabetes, heart disease, or inflammatory bowel disease require careful evaluation of how cyclosporine therapy may interact with their existing conditions and treatments. Working dogs, performance dogs, and dogs in stressful environments may have altered immune demands that should be considered in treatment planning.

Cyclosporine capsules should be stored according to manufacturer guidelines to maintain medication stability and effectiveness. The capsules should be kept at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), and protected from excessive heat and moisture. Storage in bathrooms or kitchens where humidity fluctuates is not recommended. The original container provides protection from light and helps maintain appropriate storage conditions. Blister packs should be kept intact until individual doses are needed. Pet owners should check expiration dates regularly and not use medication that has expired, as degraded drug may be less effective or potentially harmful.

Different formulations of cyclosporine may have specific storage requirements that should be followed precisely. Modified cyclosporine oral solution, if prescribed, may have different temperature requirements and should be stored according to its specific labeling. Any special storage instructions provided by the dispensing pharmacy should be followed. Some owners find that briefly refrigerating or freezing capsules before administration helps reduce gastrointestinal side effects in sensitive dogs, but this should not be done for long-term storage unless specifically directed. Always consult the product labeling or pharmacist for formulation-specific storage guidance.

Safe handling and disposal of cyclosporine protects all household members and the environment. As an immunosuppressive medication, cyclosporine should be handled with care, particularly by pregnant women or immunocompromised individuals who should avoid direct contact with the capsules. Wash hands thoroughly after administering the medication. Keep the medication stored securely out of reach of children and pets, as the capsules may be attractive to dogs due to their size and texture. Accidental ingestion of extra doses by the patient or other pets constitutes a potential emergency. Unused or expired cyclosporine should be disposed of properly through a pharmacy drug take-back program or according to local guidelines for medication disposal rather than being flushed or placed in regular household trash.

The vast majority of dog breeds tolerate cyclosporine well when it is prescribed appropriately and monitored properly. Breed considerations for cyclosporine relate primarily to the conditions being treated rather than to breed-specific drug sensitivities. German Shepherd Dogs have a high prevalence of perianal fistulas, making them one of the breeds most commonly prescribed cyclosporine for this specific indication. West Highland White Terriers, French Bulldogs, English Bulldogs, Labrador Retrievers, Golden Retrievers, and many other breeds are predisposed to atopic dermatitis and may benefit from cyclosporine therapy. Understanding breed predispositions helps veterinarians anticipate which patients may need this medication.

While cyclosporine itself is not considered a high-risk medication for dogs with MDR1 gene mutations, the broader context of drug transport proteins is relevant. Breeds commonly affected by MDR1 mutation include Collies (rough and smooth coated), Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, English Shepherds, Border Collies, Long-haired Whippets, Silken Windhounds, and mixed breeds with herding dog heritage. In these breeds, cyclosporine may interact with other medications differently, and the overall medication regimen should be evaluated by a veterinarian aware of MDR1 concerns. Genetic testing can determine MDR1 status and guide medication management in affected breeds.

Size considerations are important for practical cyclosporine administration across the tremendous size range of dog breeds. Toy and small breeds such as Chihuahuas, Yorkshire Terriers, and Maltese require precise dosing with smaller capsule sizes. Accurate body weight measurement is critical in these small patients where small weight differences can significantly affect dosing. Giant breeds such as Great Danes, Mastiffs, and Saint Bernards require multiple capsules per dose, which can affect medication cost and administration logistics. The availability of multiple capsule sizes allows veterinarians to optimize dosing accuracy across all breed sizes.

Age-related considerations apply across all breeds but may have breed-specific implications. Large and giant breed puppies mature more slowly than small breed puppies and may have prolonged periods of developing hepatic function. Senior dogs, particularly those of large breeds that age faster than small breeds, may have age-related changes in organ function that affect cyclosporine handling. Brachycephalic breeds such as Bulldogs, Pugs, and Boston Terriers, which are predisposed to both atopic dermatitis and various respiratory and metabolic conditions, require comprehensive health evaluation before starting immunosuppressive therapy. Veterinarians consider the complete clinical picture including breed, age, size, and overall health status when prescribing cyclosporine.

Several other medications may be used to manage similar conditions as cyclosporine, and understanding alternatives helps pet owners appreciate their treatment options. Oclacitinib (Apoquel) is a Janus kinase inhibitor that has become another first-line treatment for canine atopic dermatitis. It works through a different mechanism than cyclosporine and typically provides faster relief of itching, often within hours to days compared to the weeks required for full cyclosporine effect. Lokivetmab (Cytopoint) is an injectable monoclonal antibody that targets canine interleukin-31, a key itch mediator, and provides approximately four to eight weeks of relief per injection. Each of these medications has distinct advantages and considerations that make them more or less suitable for individual patients.

Different drug classes offer alternative approaches when cyclosporine is not suitable or as part of combination therapy. Corticosteroids such as prednisone provide rapid and effective anti-inflammatory and anti-itch effects but carry significant side effects with long-term use. Antihistamines including diphenhydramine, cetirizine, and hydroxyzine may provide mild relief in some dogs and are often used as adjunctive therapy. Topical therapies including medicated shampoos, sprays, and mousses containing ingredients like chlorhexidine, ceramides, or corticosteroids address skin symptoms directly. Allergen-specific immunotherapy (allergy shots or sublingual drops) addresses the underlying allergic sensitivity and may reduce medication requirements over time.

Complementary therapies can support cyclosporine treatment and overall skin health in allergic dogs. Essential fatty acid supplementation, particularly omega-3 fatty acids from fish oil, may have anti-inflammatory effects and support skin barrier function. Probiotic supplements may help modulate immune responses in some dogs. Regular bathing with appropriate shampoos removes allergens from the coat and soothes irritated skin. Environmental management including air filtration, regular bedding washing, and allergen avoidance reduces allergen exposure. Any changes to the treatment regimen, including adding supplements or complementary therapies, should be discussed with the prescribing veterinarian to ensure compatibility and avoid interactions.